<DOC>
	<DOCNO>NCT01236040</DOCNO>
	<brief_summary>This study ass safety immunogenicity GSK Biologicals ' H5N1 flu candidate vaccine GSK2590066A GSK2340273A healthy adult 18 - 49 year old .</brief_summary>
	<brief_title>Immunogenicity Safety Pandemic Influenza Vaccines Adults Aged 18 - 49 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Male female adult , 1849 year age time first vaccination . Satisfactory baseline medical assessment history physical examination . Safety laboratory test result within parameter specify protocol . Access consistent mean telephone contact Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative urine pregnancy test day first vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Medical history physicianconfirmed infection H5N1 virus . Increased risk occupational exposure H5N1 influenza virus . Previous vaccination time H5N1 vaccine , oilin water adjuvanted influenza vaccine . Planned administration adjuvanted influenza vaccine H5N1 pandemic vaccine entire study period . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Evidence current substance abuse , include alcohol , medical history . Presence temperature &gt; = 38.0ºC ( ≥100.4ºF ) , acute symptom great `` mild '' severity schedule date first dose . Diagnosed cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin , outside 24 hour prior dose , eligible . Persons receive prophylactic antiplatelet medication . An acute evolve neurological disorder history GuillainBarré syndrome . Administration inactivate seasonal influenza vaccine within 14 day first study vaccine dose , vaccine ( ) foreseen study protocol within 30 day first study vaccine dose . The administration live attenuate trivalent seasonal influenza virus vaccine ( LAIV ) allow . Planned administration vaccine ( ) foreseen study protocol completion Day 42 visit . The administration LAIV allow . Any known suspected allergy constituent influenza vaccine latex , history severe reaction previous influenza vaccination . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior first study vaccine dose . Lactating nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>H5N1</keyword>
	<keyword>Influenza</keyword>
	<keyword>Pandemic</keyword>
</DOC>